Obviously, in NSCLC patients undergoing anti-PD-1/anti-PD-L1 therapies efforts have been made to determine whether sPD-L1 are predictive of response, but so far results are ambiguous and more investigations are needed to elucidate this matter. Here, CD274 is linked to non-small cell lung carcinoma.